The CDC has updated its guidelines for Non-Occupational Post-Exposure Prophylaxis (nPEP), a critical HIV prevention strategy, urging its integration into general medical practice. According to a commentary by Dr. Roy Gulick of Weill Cornell Medicine in Annals of Internal Medicine, these streamlined recommendations aim to reduce new HIV infections by simplifying eligibility criteria and emphasizing faster treatment initiation.
The revised guidelines, last updated in 2016, now include advancements such as assessing the HIV RNA level of the source and whether the exposed individual was on PrEP. Key changes highlight the urgency of starting nPEP within 24 hours of exposure—a significant shift from the previous 72-hour window. The preferred regimen combines an HIV integrase inhibitor (bictegravir or dolutegravir) with two nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Dr. Gulick notes that candidates for nPEP should undergo HIV testing via rapid or antigen-antibody tests, with an additional RNA test recommended for those on long-acting injectable PrEP. The guidelines also introduce “PEP to PrEP,” a strategy to transition high-risk individuals to ongoing prevention.
“Incorporating these updated nPEP guidelines into routine care can transform HIV prevention efforts,” said Dr. Gulick.
By making nPEP more accessible and actionable, the CDC’s updated guidelines aim to curb HIV transmission and align prevention with modern medical practices. Future efforts will focus on expanding provider awareness and patient access to these critical tools.
Add comment